Abstract
Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings.
Author supplied keywords
Cite
CITATION STYLE
Drost, F. J. H., Nieboer, D., Morgan, T. M., Carroll, P. R., Roobol, M. J., Trock, B., … Helleman, J. (2019). Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 76(5), 693–702. https://doi.org/10.1016/j.eururo.2019.07.041
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
